Sorafenib, the oral anti-cancer drug commonly used for kidney cancer, earned the European Commission's (EC) seal of approval for , on October 30. The manufacturer, Bayer Pharmaceuticals, is now waiting for decisions from Health Canada and the FDA.
In a press release, Bayer spokesperson Arthur Higgins said,
"The approval of Nexavar (sorafenib), a novel multi-kinase inhibitor, represents an unprecedented advance for patients with hepatocellular carcinoma (HCC) who, until now, had no approved systemic treatment options."The drug -- already on the for renal carcinoma treatment -- boosts HCC patients' survival by 44%, adding up to three months to their lives. on sorafenib's dramatic results in June, when the research was presented at the American Society of Clinical Oncologists meeting in Chicago.
Check out our website: